A Study of Remibrutinib Using MR Imaging in Relapsing or Progressive MS

Official title

An Open-label, Single-center Study of Remibrutinib Using Ultra High-field (7T) MR Imaging in Relapsing or Progressive MS (RemiSeven)

Overview

The study is an investigator-run, study following participants for 2 years with twice-daily remibrutinib. MRI is the main endpoint. Safety, tolerability, and efficacy are secondary endpoints. Approximately 20 participants with relapsing or progressive forms of MS will be recruited.

Detailed description

The study is an investigator-run, open-label Phase 2 study with approximately 24 total months of observation, involving approximately 20 participants with relapsing or progressive forms of MS.

Participants will be recruited from the patient populations followed at CCF. All participants will take 100 mg remibrutinib twice daily. They will receive 4 MRIs, blood tests, EKGs, physical exams, and clinical functioning exams periodically to assess safety, tolerability, and efficacy of the study drug. All study activities will be performed at the Cleveland Clinic Mellen Center.

Interventions

• Drug Remibrutinib (Open Label)
  100 mg remibrutinib, twice daily

Primary outcome measures

• Quantitative MRI volumetric measurements [Time frame: Baseline to Month 24]
• Slowly expanding lesions (SELs) [Time frame: Baseline to Month 24]
• Paramagnetic rim lesions (PRLs) -- count [Time frame: Baseline to Month 24]
• Paramagnetic rim lesions (PRLs) -- size [Time frame: Baseline to Month 24]
• Paramagnetic rim lesions (PRLs) -- quantitative susceptibility measures [Time frame: Baseline to Month 24]
• Myelin Water Fraction [Time frame: Baseline to Month 24]
• Functional MRI (Default mode network) [Time frame: Baseline to Month 24]
• Microstructural tissue integrity [Time frame: Baseline to Month 24]
• Leptomeningeal enhancement [Time frame: Baseline to Month 24]
• Neuromelanin [Time frame: Baseline to Month 24]

Secondary outcome measures (8)

• Frequency of Treatment Emergent Adverse Events (TEAEs) [Time frame: Baseline to Month 24]
• Frequency of Serious Adverse Events (SAEs) [Time frame: Baseline to Month 24]
• Frequency of study medication discontinuation [Time frame: Baseline to Month 24]
• Gadolinium Enhancing Lesions [Time frame: Baseline to Month 24]
• Quantitative Lesion Burden [Time frame: Baseline to Month 24]
• Annualized Relapse Rate (ARR) [Time frame: Baseline to Month 24]
• Expanded Disability Status Scale (EDSS) [Time frame: Baseline to Month 24]
• Serum Neurofilament Light Chain (NfL) [Time frame: Baseline to Month 24]

Eligibility criteria

Inclusion criteria

To be eligible for the study, participants must meet the following eligibility criteria at the Screening visit:

• Written informed consent signed by participant.
• English-speaking.
• Male and female participants, 18-60 years of age inclusive.
• Established diagnosis of relapsing or progressive MS, as defined by the 2024 revision of McDonald Diagnostic Criteria (any form of MS). A diagnosis of MS must be confirmed at the time of the screening visit.
• Expanded Disability Status Score (EDSS) of 0 - 6.5, inclusive.
• Adequate vision and motor function to participate in assessment procedures.
• Females participating in the study must meet one the following criteria:

• Surgically sterilized (e.g., hysterectomy, bilateral oophorectomy or tubal ligation) for at least 6 months or postmenopausal (postmenopausal females must have no menstrual bleeding for at least 1 year) or
• If not postmenopausal, agree to use a double method of contraception, one of which is a barrier method (e.g., intrauterine device plus condom, spermicidal gel plus condom) 30 days prior to dosing until 30 days after last dose and have negative human chorionic gonadotropin (β-hCG) test for pregnancy at screening and at each follow-up visit.
• Males who have not had a vasectomy must use appropriate contraception methods (barrier or abstinence) from 30 days prior to dosing until 30 days after last dose.
• Evidence of disease activity in the prior 12 months (at least one clinical relapse or one gadolinium enhancing lesion or new T2 lesion) or presence of disability worsening based clinician's assessment in the prior 12 months.
• Participants should be in reasonably good health and neurologically stable over the last 1 month (no MS relapse in this period).

Exclusion criteria

Participants will be excluded from the study if any of the following exclusion criteria exist at the Screening Visit:

• Concurrent treatment with any disease modifying therapy for MS or systemic immunotherapy for other autoimmune or rheumatological disorders (e.g. rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel disease) according to study protocol.
• Ongoing substance abuse (drug or alcohol) or any other factor that may interfere with the participant's ability to cooperate and comply with study procedures.
• History of malignancy of any organ system (other than complete resection of localized basal cell carcinoma of the skin or in situ cervical cancer) within the past 5 years regardless of treatment or metastasis status.
• History of liver disease or liver function abnormalities at baseline including Gilbert syndrome:

i. Acute or chronic liver disease ii. Cirrhosis iii. Any degree of hepatic impairment (i.e., mild, moderate, or severe) based on Child Pugh classification.

iv. Untreated hepatitis C or active hepatitis B infection v. Alcohol intake greater than 2 drinks/day for men and greater than 1 drink per day for women vi. Transaminases (i.e., AST or ALT) > 1.5x the upper limit of normal (ULN) vii. Total bilirubin >1.5 x ULN viii. Alkaline phosphatase > 2x ULN unless caused by non-liver related disorder or explained by a stable chronic liver disorder

• History of severe renal disease or creatinine level above 1.5 x upper limit normal.
• Pregnancy, planned or current.
• History of severe depression or suicidality.
• Hematological abnormalities at screening: hemoglobin < 10 g/dl, platelets < 100000/mm3, absolute lymphocyte count < 800/mm3, white blood cells < 3000/mm3, neutrophils < 1500/mm3, B-cell count < 50% lower limit of normal, total IgG or total IgM < lower limit of normal.
• Active clinically significant bacterial, viral, parasitic, or fungal infections, in the judgement of the investigator.
• History of significant central nervous system disease (e.g. stroke, traumatic brain injury, myelopathy, progressive multifocal leukoencepahalopathy).
• History of splenectomy.
• History of active or latent tuberculosis with a positive QuantiFERON, at screening.
• Individuals with a known immunodeficiency syndrome, drug-induced immunodeficiency, hereditary immunodeficiency, or who test positive for Human immunodeficiency virus (HIV) antibody, at screening
• Clinically significant cardiovascular, renal, hepatic, endocrine, metabolic, hematological, pulmonary, or gastrointestinal disorders that in the investigator's opinion would compromise the safety of the participant or interfere with the interpretation of the study results.
• History or current diagnosis of ECG abnormalities such as concomitant clinically significant cardiac arrhythmias, history of familial long QT syndrome, cardiac arrhythmias requiring anti-arrhythmic treatment with class Ia or III anti-arrhythmic drugs.
• Resting QT interval corrected by Fridericia's formula (QTcF) >450 msec (male) or >460 msec (female) prior to screening.
• Requirement for anticoagulant medication or use of dual anti-platelet therapy. Use of acetylsalicylic acid up to 100 mg/day or clopidogrel up to 75 mg/day, is permitted.
• Significant bleeding risk or history of clinically significant bleeding disorders.
• Use of gastric acid modifying agents, such as proton pump inhibitors or H2 antagonists.
• Use of any strong or moderate inhibitors of CYP3A4 (including clarithromycin, grapefruit, itraconazole, ketoconazole), or strong or moderate inducers of CYP3A4 (including carbamazepine, phenytoin, St John's Wort, primidone, modafinil). Use of BCRP or P-glycoprotein substrates. Use of any herbal/dietary supplements 8 weeks prior to first dose of study drug or during the study period. Concomitant medicines will be examined on a case-by-case basis against the Flockhart Table by study investigator, and if needed, the Medical Monitor, to determine allowability.
• Live vaccines within 6 weeks prior to screening or requirement to receive these vaccinations at any time during study treatment.
• Inability to complete MRI with contrast (claustrophobia, pacemaker, cochlear implant, metallic implants incompatible with MR, hypersensitivity to gadolinium-based contrast agent, or severe renal disease).
• Subjects who score "yes" to items 4 or 5 of the C-SSRS suicidal ideation or any of the items on C-SSRS suicidal behavior section at screening.
• Other factors that the Investigator determines would place the individual at risk for participation or interfere with interpretation of the results.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

N/A

Model

Single group

Masking

Open label

Primary purpose

Treatment

Study locations

United States · 1 center

• Cleveland Clinic — Cleveland

Identifiers

NCT: NCT07222956 · CCF 25-1070

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗